Clinical Trials Logo

HPV-Associated Cancers clinical trials

View clinical trials related to HPV-Associated Cancers.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04799054 Recruiting - Clinical trials for Advanced Solid Tumor

A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors

Start date: March 18, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

TransCon TLR7/8 Agonist is an investigational drug being developed for treatment of locally advanced or metastatic solid tumors. This Phase 1/2 study will evaluate TransCon TLR7/8 Agonist as monotherapy or in combination with pembrolizumab in dose escalation and dose expansion. Participants will receive intratumoral (IT) injection of TransCon TLR7/8 Agonist every cycle. The primary objectives are to evaluate safety and tolerability, and define the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of TransCon TLR7/8 Agonist alone or in combination with pembrolizumab.